Archives of Ophthalmology · 2006 · 79 citations · 39 references
Life SciencesOncologyPharmacologyApoptosisMolecular Cell BiologyMolecular OncologyApoptosis In CancerApoptosis ModulationApoptosis RegulationCell DeathRna InterferenceTumor Suppressor GenesCell Death AssaysCell Survival AssaysCell Viability AssaysP53-dependent Apoptotic SignalingP53-mediated ApoptosisP53-mediated Cell DeathRetinoblastoma Family ProteinsTumor Suppressor P53
PURPOSE: To determine the efficacy of inducing p53-mediated cell death in retinoblastoma cells by Nutlin 3A, a small molecule HDM2 inhibitor. METHODS: Retinoblastoma cell lines WERI-RB-1 and Y79 were treated with Nutlin 3A. Cell viability assays, Western blot analyses, confocal microscopy, and flow cytometry were performed to measure cell survival, p53 protein levels, activation of downstream targets, and apoptosis. To determine whether the effects of Nutlin 3A were p53-dependent, cell viability assays were performed on Y79 cells expressing short interfering RNA (siRNA) against p53. RESULTS: Nutlin 3A induced cell death in Y79 and WERI-RB-1 in the 5- to 10-microM dose range. Treated cells demonstrated increased protein levels of p53 and the p53 targets p21 and HDM2. Phosphorylation of p53-serine-15, a marker for activation of p53 via genotoxic mechanisms, was absent. Y79 cells expressing siRNA against p53 demonstrated resistance to Nutlin 3A. CONCLUSIONS: Nutlin 3A induced p53-mediated apoptosis in a dose-dependent, nongenotoxic fashion in 2 retinoblastoma cell lines. CLINICAL RELEVANCE: Nutlin 3A is effective against retinoblastoma cells in a nongenotoxic manner. Because the mutagenic effects of radiation and chemotherapy may increase risks of secondary tumor formation, targeted p53 activation may be a safer alternative treatment for retinoblastoma in the future.
39
Bert Vogelstein, David P. Lane, Arnold J. Levine · Nature · 2000 · 6.6K citations
I. Vermes, C. Haanen, H M Steffens-Nakken et al. · Journal of Immunological Methods · 1995 · 5.4K citations · Full text
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15
Amplification of a gene encoding a p53-associated protein in human sarcomas
Jonathan D. Oliner, Kenneth W. Kinzler, Paul S. Meltzer et al. · Nature · 1992 · 2K citations · Full text
The p53-mdm-2 autoregulatory feedback loop.
J. Henri Bayle, David C. Olson, Arnold J. Levine · Genes & Development · 1993 · 1.8K citations · Full text